Dainippon Lays Out R&D Table Ahead Of Latuda Challenges
Focus On Novel Schizophrenia Candidate
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
You may also be interested in...
The UK firm has not completed a clinical trial yet but having raised over $350m from its NASDAQ initial public offering and an extra $160m from a private placement, Exscientia's future looks extremely bright.
Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.
BMS is impressed with Exscientia's projects with recently acquired Celgene and has signed up to use the UK firm's artificial intelligence platform to accelerate the discovery of small molecules in areas including oncology and immunology.